Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Thyroid Neoplasms 5Thyroid Cancer, Papillary 1Parkinson Disease 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Immunoglobulin Light-chain Amyloidosis 1Differentiated Thyroid Carcinoma 1Breast Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

fluorodopa F 18 2Tomography, Emission-Computed, Single-Photon 1Registries 1Positron Emission Tomography Computed Tomography 1Neuropsychological Tests 1Neurofeedback 1Medical Marijuana 1Iodine-124 1Iodine-123 1Furosemide 1Exergaming 1Clinical Laboratory Techniques 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parkinson Disease × Iodine-124 × Clear all
NCT01931488 2013-08-29

124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.

Tel-Aviv Sourasky Medical Center

Phase 2 Unknown
40 enrolled
EndocrineNET

Parkinson Disease, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡